UBX - Unity Biotechnology, Inc Growth-Adjusted Payback Ratio
Complex senolytic patents create a powerful defensive barrier for Unity Biotechnology (UBX). The PEG ratio demonstrates the current market valuation, where the 0.00 mark reflects the asset's current state. Positive momentum is expected from the Phase 2 trials of UBX1325. Currently, Unity Biotechnology relies on academic expertise while seeking to attract major partners to advance R&D.
Unity Biotechnology (UBX) - metric breakdowns and financial figures
- current quotes and average value forecast:
- market capitalization statistics:
- book capitalization indicators:
- debt obligations and liquidity statistics:
Debt to Capital Unity Biotechnology|UBX - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio unitybiotechnology.com|UBX - Company Aggregate Debts|Debts to Book Value Unity Bio|UBX - Company Long-Term Debts|Company Current Liabilities Unity Biotechnology|Intermediate Coverage Ratio unitybiotechnology.com
- financial results and valuation multiples details:
UBX - Company Net Income|Net Profit Forecast Unity Biotechnology|UBX - Price to Earnings Ratio|Projected Price to Earnings Ratio Unity Biotechnology, Inc|UBX - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Bio|UBX - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Unity Biotechnology|UBX - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year unitybiotechnology.com|UBX - Net earnings per share growth this year|Expected net earnings per share growth next year Unity Biotechnology
General company analysis:UBX - Unity Biotechnology Inc.
Professional selection of undervalued assets is based on identifying companies whose earnings expansion rates outpace their market valuation. By analyzing the relationship between valuation and earnings dynamics, an investor compares the P/E ratio with projected EPS growth, which for Unity Biotechnology (UBX) confirms high investment attractiveness due to the potential for global scaling of unique senolytics at a moderate market price.
Competing companies
TEM - Price to Earnings Adjusted for Growth Rate|Qiagen Group - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio IONS|Repligen Corporation - PEG Multiple|RNA: Price/Earnings to Growth Ratio|CRSP: PEG Multiple|WGS - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Ultragenyx Pharma|Price to Earnings Adjusted for Growth Rate Beam Tx BEAM|Price/Earnings to Growth Multiple SRPT (Sarepta Therapeutics, Inc.)|Company Value to Earnings Growth Ratio TWST|PEG Multiple TXG (10x Genomics)|Intellia Therapeutics Inc (NTLA) - Price to Earnings Adjusted for Growth Rate|Stoke - PEG Multiple|BioLife (BLFS) - Price/Earnings to Growth Multiple|WVE: PEG Multiple|mazetx.com - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Sionna Therapeutics|Growth-Adjusted P/E Ratio PRME (Prime Medicine Inc)|Price/Earnings to Growth Ratio Taysha (TSHA)|QURE - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio MeiraGTx Holdings plc MGTX|regenxbio.com - Price/Earnings to Growth Ratio|SLDB - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Ocugen Inc|PACB: PEG Multiple|Price to Net Income Growth Ratio Benitec Corp BNTC|Price/Earnings to Growth Multiple DSGN|Price to Earnings Adjusted for Growth Rate rocketpharma.com RCKT|Price/Earnings to Growth Multiple FDMT (4D Molecular Therapeutics, Inc.)|PEG Multiple lexeotx.com (LXEO)|PEG Multiple KRRO (Korro Bio)|Editas Corp - Price/Earnings to Growth Ratio|SLN: Price/Earnings to Growth Multiple|PRQR (ProQR Therapeutics N.V.) - Growth-Adjusted P/E Ratio|CDXS: PEG Multiple|Growth-Adjusted P/E Ratio SGMO|Price/Earnings to Growth Ratio Nautilus Biotechnology, Inc.|Growth-Adjusted P/E Ratio MGX (Metagenomi Therapeutics)|PEG Multiple DTIL|PEG Multiple generationbio.com (GBIO)|Boundless Bio - Price/Earnings to Growth Multiple|PEG Multiple Exicure Inc. XCUR|IMNN - Price/Earnings to Growth Ratio|PHIO (Phio Pharmaceuticals) - Growth-Adjusted P/E Ratio|MBIO: PEG Multiple|RNAZ - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple BNGO|APDN (Applied DNA Sciences Inc) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Multiple BLUE (Bluebird Bio)|IPA - Price to Earnings Adjusted for Growth Rate|Omega Therapeutics - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio OMIC|Regulus Therapeutics Inc. - PEG Multiple|SYRS: Price/Earnings to Growth Ratio|TBIO: PEG Multiple|TCON - Growth-Adjusted Market Cap to Net Income
